Research & Development

Although lamotrigine is a staple treatment for bipolar disorder and epilepsy, it triggers a dangerous systemic immune response in approximately one out of every thousand patients. Known as Stevens-Johnson Syndrome, this reaction causes severe skin detachment and organ damage. For years, doctors

In the United States, 300,000 new cases of breast cancer are diagnosed annually, many of which will eventually progress to a more resistant metastatic state. For patients facing these advanced stages, the traditional arsenal of chemotherapy and hormonal blockers often loses its efficacy over time,

Novartis and Bristol Myers Squibb have inadvertently set a new precedent for transparency as they navigate the complex safety challenges of applying oncology tools to chronic autoimmune diseases. This strategic pivot reflects a broader industry realization that the risk-benefit calculus for

The synthesis of combination therapies and early detection creates a feedback loop that amplifies the effectiveness of modern cancer treatment protocols. This paradigm shift means oncologists no longer view cancer as a static entity confined to a single organ like the lung or breast. Instead, they

By targeting the MC4R receptor with a small-molecule approach, Superluminal Medicines seeks to provide relief for patients suffering from hyperphagia and rare metabolic defects. This ambitious goal is now backed by a significant $60 million Series A funding round led by RA Capital Management, with

Industry groups are requesting concrete examples of how prior clinical data can be used to optimize dosing and streamline trial designs for rare disease therapies. This collective push follows the release of the Food and Drug Administration's draft guidance concerning the use of prior knowledge in